7 terminated, 6 completed, 4 recruiting, 2 active not recruiting. 22 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Terminated 7, Completed 6, Recruiting 4, Active not recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 2 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
Follow adagrasib: new trials by email Literature Review of adagrasib trials Research Report on adagrasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent Adagrasib - Healthy Participants | Phase 1 | Completed | Mirati Therapeutics Inc. | 10 | 2026-08-05 | 2026-09-28 |
| Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial Adagrasib, Iza-bren - Non-small Cell Lung Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-05-15 | 2026-08-11 |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors BMS-986488, Adagrasib, Cetuximab - Advanced Malignant Tumors | Phase 1 | Recruiting | Bristol-Myers Squibb | 437 | 2025-03-25 | 2026-07-29 |
| Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets Adagrasib - Healthy Volunteers | Phase 1 | Completed | Mirati Therapeutics Inc. | 160 | 2025-02-04 | 2025-07-16 |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations Cetuximab, Cemiplimab, Adagrasib - Metastatic Colorectal Cancer, KRAS G12C Mutations | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 31 | 2024-08-28 | 2026-06-26 |
| Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Adagrasib, Olaparib - Advanced Solid Tumor, Non-small Cell Lung Cancers | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2024-01-30 | 2026-04-09 |
| A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation INCB099280, adagrasib - Advanced Solid Tumors | Phase 1 | Terminated | Incyte Corporation | 6 | 2023-12-28 | 2026-09-08 |
| Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer MRTX849, Irinotecan, Cetuximab - Colon Cancer, Colorectal Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2023-12-06 | 2026-08-14 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors BMS-986466, Adagrasib, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2023-11-09 | 2025-07-22 |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Darlifarnib, Cabozantinib, Adagrasib - Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Kura Oncology, Inc. | 300 | 2023-10-18 | 2026-10-14 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC | Phase 1 | Terminated | Mirati Therapeutics Inc. | 6 | 2023-08-07 | 2025-04-25 |
| A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib Adagrasib, Eltrombopag + adagrasib - Healthy Adults | Phase 1 | Completed | Mirati Therapeutics Inc. | 16 | 2023-06-29 | 2024-03-13 |
| Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients MRTX849 - Metastatic Pancreatic Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-05-03 | 2025-07-25 | |
| A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations Durvalumab, Adagrasib - Lung Cancer, Gastro-intestinal Cancer | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-04-25 | 2024-01-23 | |
| A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway MRTX0902, MRTX849 - Solid Tumor, Advanced Solid Tumor | Phase 1 | Terminated | Mirati Therapeutics Inc. | 64 | 2022-12-02 | 2026-02-19 |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients avutometinib (VS-6766) and adagrasib - Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | Completed | Verastem, Inc. | 12 | 2022-08-01 | 2026-07-02 |
| The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors MRTX849 - Advanced or Metastatic Solid Tumor | Phase 1 | Unknown | Zai Lab (Shanghai) Co., Ltd. | 22 | 2022-05-30 | 2023-02-27 |
| Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) MRTX849, Palbociclib - Advanced Solid Tumor | Phase 1 | Completed | Mirati Therapeutics Inc. | 11 | 2022-01-20 | 2025-02-11 |
| Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) MRTX849, BI 1701963 - Advanced Cancer, Metastatic Cancer | Phase 1 | Terminated | Mirati Therapeutics Inc. | 7 | 2021-07-28 | 2024-12-16 |
| Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies Vociprotafib, Pembrolizumab, Adagrasib - Metastatic Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 65 | 2020-06-09 | 2025-05-29 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (9) · Colorectal Neoplasms (9) · Neoplasm Metastasis (7) · Neoplasms (6) · Colonic Neoplasms (5) · Pancreatic Neoplasms (4) · Lung Neoplasms (3) · Carcinoma, Renal Cell (2) · Biliary Tract Neoplasms (1) · Kidney Neoplasms (1)
Mirati Therapeutics Inc. (9) · M.D. Anderson Cancer Center (6) · Bristol-Myers Squibb (2) · Incyte Corporation (1) · Kura Oncology, Inc. (1) · Sanofi (1) · Verastem, Inc. (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (21) · Australia (3) · Spain (3) · France (2) · Italy (2) · Puerto Rico (2) · Argentina (1) · Canada (1) · Chile (1) · China (1) · Finland (1) · Germany (1) · Israel (1) · South Korea (1) · Taiwan (1)
Christine Parseghian, MD (1) · Dan Zhao, MD (1) · David S. Hong, MD (1) · MD Verastem (1) · Marcelo V Negrao, MD (1) · Marcelo V. Negrao, MD (1) · Richard Chao, MD (1) · Timothy Yap, MD (1)
PMID 34161704, PMID 35167329, PMID 35404402, PMID 35658005, PMID 36546659, PMID 37099736, PMID 37327468, PMID 38579193
2023 (2)